OR WAIT null SECS
© 2023 MJH Life Sciences and Consultant Live. All rights reserved.
The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.
January 18, 2023
Results of the PREVENT CLOT study indicate use of aspirin was as effective as low-molecular-weight heparin for reducing incidence of mortality in patients hospitalized with a traumatic fracture.
September 20, 2022
A reduction in aspirin use was associated with significantly less bleeding and health care use, without an increase in thrombotic outcomes.
August 24, 2022
A recent study indicated no evident VTE risk in patients with eczema, despite FDA black box warnings for the drug class.
July 06, 2022
New findings suggest low-dose rivaroxaban plus aspirin was associated
with lower VTE risk compared with aspirin alone.
June 17, 2022
The prevalence rate of VTE was 2% among a large population of SCD patients in Nigeria.
May 24, 2022
Data show the presence of five and six risk factors increased the risk of VTE exponentially to 10.9% and 25%, respectively
March 29, 2022
In a population aged 70 years and older, a remote history of VT was associated with an increased risk of VT independent of other factors.
March 16, 2022
Apixaban prescription beyond 90 days showed no difference in hospitalization risk for major bleeding.
February 01, 2022
Investigators noted that clinically relevant risks could not be excluded with certainty despite not seeing a statistically significant increase in corresponding risks for more rare and severe thrombotic outcomes.
January 11, 2022
A recent study showed anticoagulant therapy for 6 weeks compared to 3 months met noninferiority criteria, based on a combination of recurrent VTE risk and bleeding risk.